Phase I trial of concurrent taxotere with radiation therapy and hormonal therapy for clinically localized high risk prostate cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide; Goserelin; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 01 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Mar 2017 Planned End Date changed from 1 Jan 2011 to 1 Dec 2017.
- 28 Dec 2015 Planned primary completion date changed from 1 Dec 2012 to 1 Jan 2011, as reported by ClinicalTrials.gov.